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ARTICLE
Orthogonal Cas9–Cas9 chimeras provide
a versatile platform for genome editing
Mehmet Fatih Bolukbasi1,2,6, Pengpeng Liu1, Kevin Luk1, Samantha F. Kwok1, Ankit Gupta1,7, Nadia Amrani3,
Erik J. Sontheimer 3,4, Lihua Julie Zhu 1,4,5 & Scot A. Wolfe1,2
The development of robust, versatile and accurate toolsets is critical to facilitate therapeutic
genome editing applications. Here we establish RNA-programmable Cas9-Cas9 chimeras, in
single- and dual-nuclease formats, as versatile genome engineering systems. In both of these
formats, Cas9-Cas9 fusions display an expanded targeting repertoire and achieve highly
speciﬁc genome editing. Dual-nuclease Cas9-Cas9 chimeras have distinct advantages over
monomeric Cas9s including higher target site activity and the generation of predictable
precise deletion products between their target sites. At a therapeutically relevant site within
the BCL11A erythroid enhancer, Cas9-Cas9 nucleases produced precise deletions that com-
prised up to 97% of all sequence alterations. Thus Cas9-Cas9 chimeras represent an
important tool that could be particularly valuable for therapeutic genome editing applications
where a precise cleavage position and deﬁned sequence end products are desirable.
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The Class 2 CRISPR-Cas bacterial adaptive immune systemhas been used for a wide variety of applications since beingrepurposed for programmable genome editing and gene
regulation1,2. The development of these tools for therapeutic
genome editing applications is well underway with numerous
investigations examining ex vivo and in vivo therapeutic
approaches3,4. The Type II effector protein Cas9 from Strepto-
coccus pyogenes (SpCas9) is one of the most widely used of these
nucleases due to its robust activity and broad targeting range5,6.
Target site recognition involves Cas9 binding to its PAM recog-
nition element and complementarity of the complexed guide
RNA with the neighboring genomic sequence5,7–9. Once fully
engaged via R-loop formation, SpCas9 typically generates a blunt
double-strand break (DSBs) at the target site5. In some instances
the accuracy of wild type SpCas9 (SpCas9WT) nuclease is
imperfect, leading to cleavage of “off-target” sites within the
genome10–12. The resulting collateral damage to the genome is
undesirable for many therapeutic applications.
We and others have used protein and RNA engineering stra-
tegies to improve the speciﬁcity of SpCas9 for therapeutic genome
editing applications13,14. We previously reported that a chimera
between PAM-interaction attenuated SpCas9 (SpCas9MT) and a
programmable DNA-binding domain (pDBD; ZFP or TALE)
enhances the targeting range and speciﬁcity of SpCas915. In the
SpCas9MT-pDBD chimeras the pDBD provides an additional
stage of target site licensing prior to cleavage. The ﬁrst stage is
mediated by pDBD recognition of a sequence downstream of the
PAM. The increased effective concentration of SpCas9MT upon
pDBD binding facilitates recognition of the PAM element and
initiation of R-loop formation7,15. If sufﬁcient complementarity
exists between the sgRNA and the target site, cleavage of the DNA
strands occurs. However, building functional pDBDs requires
some level of expertise in pDBD assembly, which creates a barrier
to this platform’s adoption.
In this study, we assessed the feasibility of substituting the
pDBD within the Cas9MT-pDBD platform with an orthogonal
Cas9 from either N. meningiditis (NmCas9)16,17 or S. aureus
(SaCas9)18 to develop an entirely RNA-programmable nuclease
platform spanning two linked Cas9 domains. We constructed
these Cas9-Cas9 chimeras in both single-nuclease and dual-
nuclease formats. In the single-nuclease format, the attenuated
SpCas9MT domain is fused to a nuclease-dead NmCas9 or
SaCas9, whose orthogonal guide is programmed to target a
neighboring DNA sequence. Here the nuclease-dead Cas9
(dNmCas9 or dSaCas9) should act like a pDBD to deliver
SpCas9MT to the target site, thereby permitting target site
recognition through the increased effective concentration of the
SpCas9MT nuclease (Fig. 1a). Similar to SpCas9MT-pDBDs15,
SpCas9MT-dNm/SaCas9 chimeras achieve a high-level of speci-
ﬁcity as assessed via GUIDE-seq12 and targeted amplicon
sequencing. In the dual-nuclease format, both nucleases within
the orthogonal Cas9–Cas9 fusions are active. We hypothesized
that synchronous cleavage of the genome at two neighboring
positions will primarily produce segmental deletions with deﬁned
junctions (referred to as precise deletions), as is observed to
varying extents when independent nucleases are targeted to
neighboring sites within a genome6,19,20. When programmed to
target composite sites within the human genome, SpCas9WT-Nm/
SaCas9WT nuclease fusions produce a larger fraction of precise
deletions, as high as 97% of all lesions, than a pair of independent
Cas9 monomers used simultaneously. Similar to SpCas9-pDBD
chimeras15, Cas9–Cas9 fusions in both the single-nuclease and
dual-nuclease format expand the targeting range of SpCas9 by
allowing the recognition of suboptimal PAMs.
These dual nucleases should be particularly useful for the
disruption of therapeutically relevant regulatory elements within
a genome. In sickle cell disease, one proposed therapeutic
approach is to induce the expression of the fetal γ-globin gene by
deleting the GATA1-binding motif within the erythroid-lineage-
speciﬁc regulatory element (enhancer +58 kb) of the BCL11A
gene21–25. Here, we show that Cas9-Cas9 fusions programmed to
target sites spanning the GATA1 element can delete this reg-
ulatory element with greater efﬁciency and accuracy than separate
Cas9/sgRNA complexes.
Results
Single-nuclease Cas9 fusions facilitate accurate editing. To
identify binding site parameters necessary for functional
Cas9–Cas9 fusion activity, we used a plasmid GFP reporter
assay26 to detect DSB formation. In this assay, two protospacers
with optimal cognate PAM elements (for SpCas95,27 and
NmCas916,28 or SpCas9 and SaCas918,29) are arrayed in tandem
in four conﬁgurations with various intervening spacings (Fig. 1b
and Supplementary Fig. 1). These Cas9 target sites interrupt a
GFP coding sequence. DNA cleavage within this region can excise
the GFP-disrupting Cas9 target sites through single-strand
annealing DNA repair, which provides a readout of nuclease
activity26. In this assay, SpCas9WT displays robust nuclease
activity while the R1335K mutant (SpCas9MT3)15 has sub-
stantially reduced activity. Fusion of nuclease-dead NmCas9 or
SaCas9 to the C-terminus of SpCas9MT3 via an unstructured 66
amino acid linker (SpCas9MT3-dNmCas9 or SpCas9MT3-dSa-
Cas9) restores nuclease activity in conﬁgurations where the
SpCas9 protospacer is upstream of the orthogonal Cas9 target site
(Fig. 1b). Notably, C-terminal fusions of dNm/SaCas9 are more
successful at restoring the loss of activity of SpCas9MT3. N-
terminal fusions of dNm/SaCas9 to SpCas9MT3
(dNmCas9–SpCas9MT3 or dSaCas9–SpCas9MT3) were less active
in the GFP reporter assay with the single linker conﬁguration that
we tested (Supplementary Fig. 1b).
In our pilot experiments at genomic target sites, Cas9–dCas9
fusions displayed a low level of editing activity. We reasoned that
this could be due to poor nuclear localization of the fusion
protein exacerbated by the less efﬁcient expression of the
Cas9–Cas9 fusion protein (Supplementary Fig. 1). Immunoﬂuor-
escent imaging of the Cas9–Cas9 fusions indicated that the
position and number of nuclear localization signals (NLSs)
impact nuclear import efﬁciency of the Cas9–Cas9 fusions
(Supplementary Fig. 1). NLSs within the linker between the two
Cas9 domains appeared to have little function. Addition of NLSs
at N and C termini achieved efﬁcient nuclear localization of the
Cas9–Cas9 fusions. We used this architecture for the remainder
of this study.
We believe that the enhancement of SpCas9MT3 nuclease
activity in the context of the SpCas9MT3–dSaCas9 fusions is due
to its increased effective concentration near the dSaCas9-binding
site. If this hypothesis is valid, nuclease activity should be
dependent on the separation between the SpCas9 and SaCas9-
binding sites. Deﬁning the distance dependence of this behavior
provides a framework for calculating the density of target sites
genome-wide that are accessible to the Cas9–Cas9 fusions. To
assess the distance constraints for the fusion protein, we
examined the editing activity of SpCas9MT3-dSaCas9 for a target
site in the AAVS1 locus as a function of the intervening distance
between a common SpCas9 target site and a series of dSaCas9
target sites shifted progressively further away (Fig. 1c, Supple-
mentary Fig. 2 and Supplementary Data 1). These data reveal an
enhancement in SpCas9MT3 activity in the fusion protein for a
separation distance of <200 bp between the two binding sites.
Beyond this distance the activity of the attenuated SpCas9MT3
reverts to that of the unfused nuclease.
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One of the salient features of the SpCas9MT-pDBD chimera is
the improved speciﬁcity of this platform relative to SpCas9WT
(Ref 15.). To evaluate the speciﬁcity of Cas9–Cas9 fusions, we
programmed SpCas9MT3–dNmCas9 and SpCas9MT3–dSaCas9
fusions to recognize a SpCas9 site (VEGFA-TS3)10,12, which has
numerous highly active off-target sites (Fig. 2a). At the VEGFA-
TS3 site, both SpCas9MT3–dNmCas9 and SpCas9MT3–dSaCas9
fusions display similar levels of on-target activity (Fig. 2b and
Supplementary Data 1). We used GUIDE-seq12 to assess the
genome-wide speciﬁcity of these nucleases. In comparison to
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Fig. 1 Development of a functional Cas9–Cas9 nuclease framework. a Schematic of SpCas9MT–dNm/SaCas9 fusions. PAM-interaction attenuated
SpCas915 (yellow star) is C-terminally fused to a nuclease-dead Cas9 from N. meningiditis or S. aureus. Each Cas9 is loaded with its cognate sgRNA. b Top,
schematic of parameters tested for target site organization. Four composite target site conﬁgurations are tested (D1:D4). The red arrow and rectangle
represent the SpCas9 protospacer (in 5′–3′ orientation) and PAM, respectively, whereas the blue arrow and rectangle represent the Nm/SaCas9
protospacer (in 5′–3′ orientation) and PAM, respectively. Two dashed lines indicate the edges of each orthogonal Cas9-binding site, and x represents the
number of intervening nucleotides. Bottom, activity proﬁles of SpCas9 (blue), SpCas9MT3 (R1335K; gray), and C-terminal fusions for
SpCas9MT3–dNmCas9 (pink), and SpCas9MT3-dSaCas9 (purple) in the GFP reporter assay. GFP reporter assay data are from three independent biological
replicates performed on different days in HEK293T cells. c Changes in the activity proﬁle of SpCas9MT3-dSaCas9 nuclease as a function of the distance
between sgRNA-binding sites at the AAVS1 locus. Top, schematic of the orientation of the target sites, where the SpCas9 site is ﬁxed and the SaCas9 site is
shifted away various distances to examine its distance-dependent activity (Supplementary Fig. 2) Bottom, deep sequencing data are from three
independent biological replicates performed on different days in HEK293T cells, where the orientation and spacing between the orthogonal Cas9 sites is
indicated below the x-axis (Supplementary Data 1). Error bars indicate ± s.e.m
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SpCas9WT, both SpCas9MT3–dNmCas9 and SpCas9MT3–dSaCas9
fusions have a substantially reduced number of GUIDE-seq peaks
(Fig. 2c and Supplementary Data 2). In addition to the reduction
in the numbers of GUIDE-seq peaks, the Speciﬁcity Ratios
(number of unique capture events at the target site divided by
sum of unique capture events at all off-target sites) for the
SpCas9MT3–dNmCas9 and SpCas9MT3–dSaCas9 fusions are
higher than for SpCas9WT (Fig. 2d and Supplementary Data 2).
To validate the off-target editing rates, we used targeted amplicon
deep sequencing for a representative set of off-target sites within
the genomes of the treated cells. Despite being comparably active
to SpCas9WT at the target site, SpCas9MT3–dNmCas9 and
SpCas9MT3–dSaCas9 fusions present dramatically better discri-
mination against near-cognate off-target sites (Fig. 2e and
Supplementary Data 1). Overall, GUIDE-seq and targeted
amplicon deep-sequencing datasets indicate that
SpCas9MT–dNm/SaCas9 fusions substantially improve the speci-
ﬁcity of SpCas9WT similar to the levels of achieved by SpCas9-
pDBDs15.
Cas9-Cas9 dual nucleases generate precise deletions. Unlike
SpCas9-pDBDs, the Cas9–Cas9 fusions can also be used as dual
nucleases. We hypothesized that when a pair of Cas9 nucleases
dock together on a target site, they will generate two DSBs syn-
chronously. Since rejoining of the broken ends without resection
via canonical NHEJ (cNHEJ) is the predominant DSB repair
response in mammalian cells30, the primary editing outcome of
Cas9–Cas9 dual nucleases should be the precise deletion of the
intervening segment between the cleavage sites. Previous studies
have demonstrated that wild-type Cas9 nucleases that are targeted
to a pair of neighboring genomic sequences can produce precise
deletions but with variable efﬁciencies6,19,20. Such variability in
editing outcomes is possibly due to asynchronous cleavage arising
from differences in the efﬁciency of recognition or cleavage by the
nuclease at two different sequences. Cas9–Cas9 dual nucleases
should improve the level of synchrony by delivering both
nucleases simultaneously to a pair of target sequences.
To test this hypothesis, we programmed SpCas9WT-NmCas9WT
dual nucleases to target the VEGFA locus in HEK293T cells. PCR
ampliﬁcation of the VEGFA locus from nuclease-treated cells
indicates that dual-Cas9 nucleases, either independently or as
fusions, generate precise segmental deletions, as anticipated
(Fig. 3a, Supplementary Fig. 3). In principle, two DSBs at a
nearby locus in the genome can produce at least six possible repair
outcomes: random indels at the ﬁrst nuclease cut site (SpCas9
indel), random indels at the second nuclease cut site (NmCas9
indel), random indels at both nuclease cut sites (Sp&NmCas9
indel), precise deletions, imprecise deletions, and inversions. To
monitor the presence and distribution of each set of repair events
quantitatively, we applied targeted amplicon deep sequencing of
the genomic DNAs from cells treated with the different nuclease
platforms. Analysis of the VEGFA amplicon sequencing data
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Fig. 2 SpCas9MT–dSa/NmCas9 fusions improve the speciﬁcity of editing. a Sequences of dual Cas9 genomic target sites at the VEGFA locus. The SpCas9
protospacer is bold underlined with its PAM is in red, the SaCas9 protospacer is double underlined with its PAM is green, and the NmCas9 protospacer is
wavy underlined with its PAM in blue. b Lesion rates of the nuclease platforms are determined by deep sequencing. c, d Genome-wide off-target analysis of
the nuclease platforms determined via GUIDE-seq12 (Supplementary Data 2). c The number of off-target peaks detected for the given nuclease. d Fold
improvement of the speciﬁcity ratio of the Cas9MT–dCas9 framework relative to SpCas9WT. e Deep sequencing determined lesion rates of the nucleases at
a small set of off-target sites discovered within the GUIDE-seq data. GUIDE-seq result is from a single experiment, whereas amplicon deep sequencing data
are from three independent biological replicates performed on different days in HEK293T cells (Supplementary Data 1). Error bars indicate ± s.e.m
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indicates two superior features of Cas9–Cas9 dual nuclease fusions
(SpCas9WT–NmCas9WT, SpCas9MT–NmCas9WT) over two inde-
pendent Cas9s (SpCas9WT+NmCas9WT): Cas9–Cas9 fusions
display higher levels of genome modiﬁcation and a higher
proportion of these editing events are precise deletions than are
observed for two independent Cas9 nucleases (Fig. 3b and
Supplementary Data 1). We observed similar editing outcomes for
SpCas9 and SaCas9 dual nucleases (Supplementary Fig. 4 and
Supplementary Data 1).
To test the generality of this phenomenon, we screened an
additional 41 genomic sites for the activity proﬁles of single and
dual nucleases, and for the types of lesions that are produced
within the genome. Overall, SpCas9 has a higher median nuclease
activity than SaCas9 and NmCas9. The lesion rates of the dual
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Prism, where the box represents the 25th and 75th percentile and the middle line is the median. Whiskers and outliers are deﬁned by the Tukey method.
Statistical signiﬁcance is determined by one-way analysis of variance (ANOVA), ** and **** denote P < 0.01 and P < 0.0001, respectively. Deep sequencing
data are from three independent biological replicates performed on different days in HEK293T cells (Supplementary Data 1). Error bars indicate ± s.e.m
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independent nucleases are similar to the levels achieved by
SpCas9 alone, but the composition of editing outcomes differs
due to the production of precise deletions (Supplementary Fig. 5
and Supplementary Data 1). In comparison to dual independent
nucleases, Cas9–Cas9 dual nucleases not only have higher overall
activity, but also produce precise segmental deletions more
efﬁciently (Supplementary Fig. 5 and Supplementary Data 1).
Next, we selected a representative set of 12 sites from these
41 sites that span different activity proﬁles for the individual
nucleases to assess in greater depth the nuclease activities of single
and dual nucleases for wild-type and PAM-interaction-deﬁcient15
forms. SpCas9WT–Sa/NmCas9WT dual-nuclease fusions have
higher overall activity than SpCas9 and two independent Cas9s
(Fig. 3c and Supplementary Data 1). This enhancement is likely
due to cooperativity between the fused nucleases, where strong
binding of one of the Cas9s increases the effective concentration
and consequently the activity of the other nuclease. The total
activity levels of SpCas9MT–Sa/NmCas9WT fusions are associated
with the activity levels of the orthogonal Cas9:sgRNA complexes
(Supplementary Fig. 6 and Supplementary Data 1).
SpCas9WT–Sa/NmCas9WT dual-nuclease fusions double the
production of precise deletions relative to two independent Cas9s
(Fig. 3d and Supplementary Data 1). More importantly, precise
deletions are the predominant products of Cas9–Cas9 dual
nucleases, encompassing on average >90% of all lesion types
(Fig. 3e, Supplementary Fig. 6 and Supplementary Data 1).
To determine the distance dependence for the synergistic
deletion of sequence elements by Cas9–Cas9 fusions, we compared
the activity of the SpCas9WT–SaCas9WT nuclease fusions to the
independent nucleases at the sites with progressively greater
separation between the Cas9-binding sites at the AAVS1 locus
(Supplementary Fig. 2). Similar to the data obtained for the
SpCas9MT3–dSaCas9 fusions at this locus, we observed signiﬁcantly
higher rates of precise deletions for the dual nuclease fusions
compared to the independent nucleases up to a separation of ~200
bp between the Cas9 target sites (Fig. 4, Supplementary Fig. 7, and
Supplementary Data 1). Beyond this 200 bp threshold the fusion
proteins behave like independent nucleases based on the decreased
rates of precise deletions. These data suggest that generation of two
synchronous nearby breaks by Cas9–Cas9 dual nucleases are
preferentially repaired via cNHEJ, and that the fusion proteins can
function synergistically over modest distances within the genome.
Deﬁning the targeting range of the Cas9–Cas9 fusions. Another
salient feature of SpCas9–pDBD fusions is their increased tar-
geting range achieved through their functionality at suboptimal
PAM sequences15. To examine the targeting range of Cas9–Cas9
fusions, we designed several SpCas9 guides that target proto-
spacers with suboptimal PAMs in tandem with an SaCas9 target
site with an optimal N2GRRT PAM sequence18 (Supplementary
Fig. 8). Wild-type SpCas9 has very low or no activity on these
sites, as expected (Fig. 5a and Supplementary Data 1). However,
in single-nuclease and dual-nuclease formats, SpCas9–SaCas9
fusions display nuclease activity at the SpCas9 sites with NAG,
NTG, NCG, NGA, NGT, and NGC suboptimal PAMs. These data
reﬂect the ability of the SpCas9–SaCas9 fusions to utilize the
presence of a single guanine in the SpCas9 PAM element as a
functional cleavage site (Fig. 5a and Supplementary Data 1).
One of the challenges to employing the Cas9–Cas9 system for
targeted genome editing is the density of potential target sites
given the requirement for two different PAM sequences. This
problem is partially mitigated by the ﬂexibility of the target site
orientation and spacing for Cas9–Cas9 fusions (Fig. 1b, c), the
ability to employ different orthogonal nucleases (SaCas9 or
NmCas9), and the ability for SpCas9 to utilize alternate PAM
sequences in the context of the fusion. We computationally
estimated the number of potential target sites for both
SpCas9–SaCas9 and SpCas9–NmCas9 fusions within the human
genome based on two different criteria: optimal PAMs for both
nucleases and conservative distance constraints (30 bp maximum
separation; “canonical targets”), or alternate PAM sequences for
SpCas9 with an optimal Sa/NmCas9 PAM and relaxed distance
constraints (100 bp maximum separation; “expanded range”).
Reassuringly, the conservative parameters indicate that
SpCas9–SaCas9 fusions have about three-fold fewer target sites
than SpCas9, and the relaxed parameters indicate that
SpCas9–SaCas9 fusions have 2.5-fold more target sites than
SpCas9 (Supplementary Fig. 8 and Supplementary Data 4). There
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are fewer targetable sites for SpCas9–NmCas9 fusions, due to the
more restrictive NmCas9 PAM requirement, but the number of
predicted SpCas9–NmCas9 target sites under the relaxed
parameters is similar to that for SpCas9.
Cas9–Cas9 nucleases accurately delete regulatory elements.
Increased nuclease activity, enhanced targeting range, and the
generation of uniform editing products favor the Cas9–Cas9 dual
nucleases for the disruption of a gene or a regulatory element
within genome. To apply this platform at a therapeutically rele-
vant genomic locus, we tested the ability of Cas9–Cas9 dual
nucleases to delete the GATA1-binding motif within the BCL11A
erythroid-lineage-speciﬁc enhancer (+58 kb) element21,22. Dis-
ruption of this regulatory element in CD34+ hematopoietic stem
and progenitor cells (HSPCs) silences BCL11A expression in the
erythroid lineage, and thereby increases production of fetal γ-
globin protein in differentiated red blood cells23. Ex vivo genome
editing of this locus in HSPCs in conjunction with autologous
bone marrow transplantation is a potential therapeutic approach
for the treatment for sickle cell disease24,25.
To efﬁciently delete the GATA1-binding motif, we pro-
grammed Cas9–Cas9 fusions to target 12 different sites spanning
this regulatory element in HEK293T cells (Supplementary Fig. 9).
Similar to our analysis at other genomic loci, Cas9–Cas9 fusions
effectively generate precise segmental deletions at most but not all
of the examined sites (Supplementary Fig. 10 and Supplementary
Data 1). Notably, in SpCas9WT–Sa/NmCas9WT dual-nuclease
fusion format, all three Cas9s (Sp/Nm/SaCas9s) effectively cut
protospacers with suboptimal PAM sequences: SpCas9 at NAG
PAMs27 (GATA1-TS7, TS8, TS9, TS10, and TS11) and GATA1-
TS5 and TS9), NmCas9 at N4GCTT (GATA1-TS4), N4GTTT
(GATA1-TS5), and N4GACT (GATA1-TS6) PAMs16,28, SaCas9
at N2GGGC (GATA1-TS10), and N2GAGG (GATA1-TS12)
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PAMs18,29. Among the 12 sites, we focused on four with the most
promising activity, GATA1-TS7, GATA1-TS9, GATA1-TS10,
and GATA1-TS11, for further characterization and speciﬁcity
analysis (Fig. 5b and Supplementary Data 1).
One potential caveat for the accurate quantiﬁcation of the
lesion products produced at the target site is the PCR
ampliﬁcation bias of a precise deletion product due to its shorter
length31. To address this possibility, we developed an assay based
on unique-molecular identiﬁers (UMI)32 and linear
ampliﬁcation-mediated (LAM) PCR33 (Supplementary Fig. 11).
In this approach, the genomic DNA is pre-ampliﬁed linearly with
a single primer that is locus-speciﬁc, and that contains UMI and
non-cognate adaptor sequences. Next, the UMI-containing
single-stranded DNA is selectively ampliﬁed and barcoded for
deep sequencing. We used the UMI-correction method to
measure the lesion proﬁles of four GATA1 target sites within
the BCL11A enhancer+58 kb locus. For single nucleases, there is
no signiﬁcant difference in the total lesion levels between bulk
and UMI-corrected analyses. For dual nucleases, there is slight
overestimation of the precise deletion levels in bulk sequencing
data relative to the UMI-corrected analysis (Supplementary
Fig. 11 and Supplementary Data 1).
Since many of the SpCas9 target sites in the BCL11A locus have
suboptimal NAG PAMs, the activity levels of monomeric SpCas9
are modest at these target sites. Cas9–Cas9 dual nucleases display
increased activity at all of these target sites relative to the dual
independent nucleases. Notably, Cas9–Cas9 fusions containing
the attenuated R1333S SpCas9 mutant (SpCas9MT2)15 also retain
high activity at all four target sites with NAG PAMs, concordant
with our previous ﬁndings (Fig. 5c and Supplementary Data 1).
Similar to previous observations at other sites, even after UMI-
correction, up to 97% of all lesions generated by Cas9–Cas9 dual
nucleases are precise deletions (Fig. 5c and Supplementary
Data 1). We performed activity assessments for the Cas9–Cas9
fusions at the GATA1-TS9 site in Jurkat and K562 cells, where we
obtained similar relative activities and distributions of editing
end-products as were observed in HEK293T cells (Supplementary
Fig. 12). These data suggest that Cas9–Cas9 dual nucleases are a
promising platform for the generation of uniform editing
products at therapeutically important sites.
To evaluate the targeting speciﬁcity of these nucleases at the
four GATA1 target sites, we performed GUIDE-seq genome-wide
speciﬁcity analysis12. We screened for active off-target sites for
each individual wild-type Cas9 and the wild type Cas9–Cas9 dual
nucleases. We observed robust GUIDE-seq oligonucleotide
incorporation at the target sites for all of the wild-type Cas9–Cas9
dual nucleases (Fig. 6a). A small number of potential off-target
sites were identiﬁed for the TS7 and TS9 target sites based on the
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GUIDE-seq analysis. A larger number of off-target sites
were associated with the SaCas9 guide for the TS11 target site.
The number of off-target sites identiﬁed by GUIDE-seq and the
unique counts that are associated with each site are similar
between the Cas9–Cas9 fusions and the individual Cas9 nucleases
(Supplementary Data 2), suggesting that there is not a dramatic
difference in the off-target activity between the individual
nucleases and the Cas9–Cas9 fusions. The three off-target sites
identiﬁed for NmCas9 have nine-nucleotide mismatches to the
guide sequence, and are so divergent that they potentially
represent false-positive sequences.
To assess the editing rate at potential off-target sites, we
performed amplicon deep sequencing at these regions within the
genome. We evaluated ten potential off-target sites for each
nuclease, which were identiﬁed by either the GUIDE-seq
analysis12 or computationally predicted via Cas-OFFinder34 (for
TS7, TS9, and TS10) when insufﬁcient high-quality sites were
identiﬁed by GUIDE-seq (Supplementary Data 3). We evaluated
the off-target activities of two different versions of the Cas9–Cas9
dual-nuclease fusions, SpCas9WT–Sa/NmCas9WT or
SpCas9MT2–Sa/NmCas9WT, in comparison with the independent
SpCas9WT and Sa/NmCas9WT nucleases delivered simulta-
neously. The deep sequencing analysis indicates that the
Cas9–Cas9 dual nuclease fusions display similar levels of off-
target activity when compared to independent dual-Cas9
nucleases. Very low levels of mutagenesis (potentially
background-level sequencing errors) were observed at the TS7
and TS10 off-target sites. More substantial mutagenesis was
observed at two of the TS9 and many of the TS11 off-target sites.
At two of the SpCas9 off-target sites (OT9-4 and OT9-8), the use
of the attenuated SpCas9MT2-SaCas9WT nuclease dramatically
reduces the off-target activity compared to the independent wild-
type SpCas9 or the SpCas9WT–SaCas9WT nuclease, without a loss
of on-target activity (Fig. 6b). These data demonstrate that
Cas9–Cas9 dual nucleases achieve robust editing at the target site
without generating a new class of off-target sites. The generation
of uniform, accurate editing products within the BCL11A
enhancer +58 kb locus highlights the utility of Cas9–Cas9 dual
nucleases as a promising genome editing platform for the deletion
of therapeutically relevant regulatory elements24,25.
Discussion
In this study, we have expanded the CRISPR/Cas9 toolset by
developing orthogonal Cas9–Cas9 chimeras in single-nuclease
and dual-nuclease formats. Unlike the original Cas9-pDBD
platform, which required some expertise in protein engineering,
the entirely RNA-programmable Cas9–Cas9 fusions should be
completely accessible to the broader scientiﬁc community. In
both single-nuclease and dual-nuclease formats, Cas9–Cas9
fusions act similarly to SpCas9-pDBDs with regards to enhanced
targeting range and improved speciﬁcity15. The presence of a
single guanine within the PAM is sufﬁcient for SpCas9 to cleave
its targets in the context of Cas9–Cas9 fusions. In principle,
similar suboptimal PAM usage should be applicable for SaCas9
and NmCas9 when the SpCas9 targets an optimal NGG PAM
element. For homology-directed repair applications, the ability to
target sites with suboptimal PAM elements may allow
Cas9–dCas9 fusions to generate a DSB closer to the site of the
desired sequence conversion35. This feature can also be useful for
allele-speciﬁc targeting by Cas9–dCas9 nucleases by placing the
PAM recognition at a polymorphic site. In the dual-nuclease
format, SpCas9WT–Sa/NmCas9WT fusions display superior
nuclease activity and primarily produce uniform, predictable
lesions within the targeted genome. These fusions are also com-
patible with PAM-interaction-attenuated SpCas9 to provide an
additional level of target site speciﬁcity. Finally, we believe that
the Cas9–Cas9 framework is not limited to the Cas9s utilized in
this study, but that it should prove general and can be used with
alternate Cas9s or perhaps even Cas12a36, where the choice of the
composite system (e.g. SaCas9 or NmCas9) will be dependent on
the available PAMs within the desired target sequence and the
orthogonality of the guide RNAs. Overall, RNA-programmable
Cas9–Cas9 fusions offer superior features to independent
nucleases: expanded targeting range, improved speciﬁcity, and
efﬁcient generation of uniform editing products.
Our analysis of the DNA repair products produced by
Cas9–Cas9 fusions provides insights into methods to increase the
efﬁciency of DSB-mediated genome sequence alterations by pro-
grammable nucleases. cNHEJ is typically the default choice for DSB
repair in most stages of the cell cycle30. Precise ligation by cNHEJ of
the ends of a DSB generated by a single nuclease restores the target
site sequence, and in the context of an active nuclease leads to
repeated cycles of cleavage and repair until imprecise repair occurs
disrupting the target sequence. The predominant production of
precise deletions after the generation of two synchronous blunt
DSBs at a composite target site supports the cellular preference for
cNHEJ for DSB repair. The ability of precise DNA repair to “mask”
nuclease activity, which is normally evident only as sequence
alterations resulting from imprecise repair, is evident from the dual
nuclease experiments. This is particularly striking for dual nucleases
at target sites where one of the Cas9 monomers is weakly active,
such as at some of the Nm/SaCas9 target sites (TS5, TS7, and TS12;
Supplementary Fig. 10) or at SpCas9 protospacers with suboptimal
PAMs (Fig. 5a). DNA cleavage at these sites by an independent
nuclease is inefﬁcient, and since precise cNHEJ repair can restore
the native DNA sequence, they are marked by low lesion rates.
However, Cas9 nucleases employed in combination reveal the
activity of the weak nuclease in the form of increased precise
deletions between the cleavage sites. This distinction in repair end
products between single nucleases and paired nucleases may
underlie differences in the activity proﬁles of SpCas9MT–dSaCas9
and SpCas9WT–SaCas9WT nucleases at some target sequences
(Figs. 1c and 4). The increase in indel rates for the fusion pro-
teins over an independent nuclease could also be due in part to
the relaxation of the local chromatin architecture as observed
for proximal CRISPR targeting37. The one disadvantage of the
production of efﬁcient precise deletions by the dual nuclease
system is that this system will likely prove less effective for
homologous recombination than a single Cas9 nuclease that
can potentially repeated cleave a site that is repaired precisely by
cNHEJ.
One of the hurdles for therapeutic genome editing applications
is the uncertainty of the functional activity of the lesions that are
produced by individual nucleases when relying on imprecise
DNA repair. At a therapeutically relevant site, Cas9–Cas9 dual
nuclease fusions produce deﬁned precise deletions comprising up
to 97% of the modiﬁed genomes, which should produce speciﬁc
alleles that have activities that can be deﬁned in model systems
prior to advancement in therapeutic applications. Cas9–Cas9
fusion-mediated production of precise deletions should be
applicable to the development of therapeutic genome editing
strategies for a number of genetic disorders. As the immediate
extension of the results described in this study, efﬁcient excision
of the core regulatory elements within the BCL11A erythroid
enhancer in CD34+ HSPCs via ex vivo delivery of Cas9–Cas9
ribonucleoproteins is likely to achieve higher rates of inactivation
than the production of local indels by a single nuclease21–23. This
increased efﬁciency should improve the therapeutic potency of
the resulting cell product when autologously transplanted back
into a patient for the treatment of β-hemoglobinopathies, such as
sickle cell disease24.
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Methods
Plasmid constructs. Our SpCas9-Sa/NmCas9 experiments employed the following
plasmids: All sgRNAs are individually expressed under a U6 promoter from a
pBluescript II SK(+)-based vector. All single-Cas9 or dual-Cas9 nuclease con-
structs are expressed via a CMV IE94 promoter from a pCS2-Dest gateway plas-
mid15. NmCas9 and SaCas9 open-reading frames for nuclease construction were
obtained from Addgene (#48670 & #61591). The nuclease-dead versions of these
constructs (dNmCas9: D16A, D587A, H588A and N611A; dSaCas9: D10A and
N580A) are generated via site-directed mutagenesis. Sequences of representative
SpCas9–SaCas9 and SpCas9–NmCas9 constructs used within this study are listed
in Supplementary Data 5. These plasmids will be deposited to Addgene for com-
munity distribution. We used the single-strand annealing-based plasmid reporter
assay developed by Porteus laboratory26 to monitor nuclease activity. Nuclease
target sequences are cloned into the M427 plasmid in between EcoRI and SbfI sites.
Cell culture and transfection/electroporation. The Human Embryonic Kidney
(HEK293T), K562 and Jurkat cell lines were gifts from our collaborators M. Green,
L. Castilla, and H. Göttlinger, respectively (all at UMass Medical School, Worcester,
MA, USA). All three cell lines were authenticated by University of Arizona
Genetics Core and tested for mycoplasma contamination at regular intervals.
HEK293T were cultured in high glucose DMEM with 10% FBS and 1% Penicillin/
Streptomycin (Gibco) in a 37 °C incubator with 5% CO2. The K562 and Jurkat cell
lines were maintained in RPMI 1640 medium with 10% FBS and 1% Penicillin/
Streptomycin (Gibco) in a 37 °C incubator with 5% CO2. We used cells at a passage
number from 5 until 25 for transient transfection to assay nuclease activity. In 24-
well format, about 1.6 × 105 cells were transfected by Polyfect transfection reagent
(Qiagen) according to the manufacturer’s suggested protocol. For Jurkat cells and
K562 cells, 2 × 105 cells were used per electroporation using Neon® Transfection
System 10 L Kit (Thermo Fisher Scientiﬁc) using the suggested electroporation
parameters: Pulse voltage (1350 v), Pulse width (10 ms), Pulse number (3). For both
single and dual nucleases we used 50 ng of each sgRNA-expressing plasmid and 50
ng mCherry-expressing plasmid, 50 ng of single nuclease (SpCas9 or NmCas9 or
SaCas9) or 100 ng Cas9–Cas9 fusion expressing plasmid. In addition, pBluescript II
SK(+) was added to the co-transfection mix to bring the total DNA mass to 300 ng
per transfection. For the SSA-reporter assay, an additional 150 ng M427 reporter
plasmid was added.
GFP-reporter assay. 48 h post-transfection cells are trypsinized and harvested into
a microcentrifuge tube. Cells are centrifuged at 500×g for 2 min, washed once with
1× PBS, recentrifuged at 500×g for 2 min and resuspended in 1× PBS for ﬂow
cytometry (Becton Dickonson FACScan). 10,000 events were counted from each
sample for FACS analysis. To adjust the transfection efﬁciency differences in
between samples, cells were initially gated for mCherry-expression, and the per-
centage of EGFP-expressing cells (nuclease-positive events) were quantiﬁed within
mCherry-positive cells. Experiments were performed in three replicates on dif-
ferent days. The data are reported as mean values with error bars indicating the
standard error of the mean.
Immunoﬂuorescence. HEK293T cells are transfected in six-well format via
Polyfect transfection reagent (Qiagen) using the manufacturer’s suggested protocol
with 300 ng Cas9–Cas9 fusion expression plasmid and 150 ng of each sgRNA
expression plasmid on a cover slip. 48 h following transfection, transfection media
was removed, cells were washed with 1× PBS and ﬁxed with 4% formaldehyde in
1× PBS for 15 min at room temperature. Following blocking (blocking solution: 2%
BSA, 0.3% Triton X-100, within 1× PBS), samples were stained with mouse anti-
hemagglutinin (Sigma, H9658, 1:500), and Alexa 488 donkey anti-mouse IgG (H
+L; Invitrogen, A-21202, 1:2000), sequentially. VECTASHIELD mounting med-
ium with DAPI (Vector Laboratories, H-1200) was used to stain the nuclei and to
mount the samples on slide. Images were taken with Zeiss AxioPlan 2 IE Motorized
Microscope System.
Western blot analysis. HEK293T cells were transfected with 50 ng of single
nuclease (SpCas9 or NmCas9 or SaCas9) or 100 ng Cas9–Cas9 fusion expressing
plasmid by Polyfect transfection reagent as described above. 48 h after transfection,
cells are harvested and lysed with 100 µl RIPA buffer. 8 µl of cell lysate is used for
electrophoresis and blotting. The blots are probed with anti-HA (1:2000; Sigma
#H9658) and anti-β-actin (1:2500; Sigma # A5316) primary antibodies; then HRP-
conjugated anti-mouse IgG (1:10,000; Abcam #ab6808) secondary antibody.
Visualization employed Immobilon Western Chemiluminescent HRP substrate
(EMD Millipore #WBKLS0100). The transfection and western blot experiments
were performed in triplicate. Quantiﬁcation of the western blot data were per-
formed by measuring the intensity of the hybridization signals using the ImageJ
analysis program38.
Target and off-target lesion analysis by deep sequencing. Library construction
for deep sequencing is modiﬁed from our previous report15. Brieﬂy, 72 h after
transfection, cells are harvested and genomic DNA extracted with GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma). Genomic loci spanning the
target and off-target sites were PCR ampliﬁed with locus-speciﬁc primers carrying
tails complementary to the Truseq adapters (Supplementary Data 3). 50 ng input
genomic DNA was PCR ampliﬁed with Q5 High-Fidelity DNA Polymerase (New
England Biolabs): (98 °C, 15 s; 67 °C 25 s; 72 °C 20 s) ×30 cycles. For the con-
struction of the UMI-based library, 50 ng input genomic DNA was ﬁrst linearly
pre-ampliﬁed with 10 nM ﬁnal concentration 5p-BCL11A_enh58_UMI primer
using the Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98 °C, 60 s;
67 °C, 25 s; 72 °C, 20 s) × 10 cycles. To the same reaction mix, 500 nM ﬁnal con-
centration 5p-DS_constant and 3p-BCL11A_enh58_DS primers were added for
another round of ampliﬁcation (98 °C, 60 s; 67 °C, 25 s; 72 °C, 20 s) for 30 cycles.
Next, 0.1 µl of each PCR reaction was ampliﬁed with barcoded primers to recon-
stitute the TruSeq adaptors using the Q5 High-Fidelity DNA Polymerase (New
England Biolabs): (98 °C, 15 s; 67 °C, 25 s; 72 °C, 20 s) x10 cycles. Equal amounts of
the products were pooled and gel puriﬁed. The puriﬁed library was deep sequenced
using a paired-end 150 bp Illumina MiSeq run with the exception of the AAVS1
extended deletion analysis, which employed a paired-end 250 bp Illumina MiSeq
run.
MiSeq data analysis was done with the help of Unix-based software tools. First,
we employed FastQC39 to determine the quality of paired-end sequencing reads
(R1 and R2 fastq ﬁles). Next, we used paired end read merger (PEAR)40 to pool raw
paired-end reads and generate single merged high-quality full-length reads. Reads
were then ﬁltered according to quality via FASTQ41 for a mean PHRED quality
score above 30 and a minimum per base score above 24. After that, we used BWA
(version 0.7.5) and SAMtools (version 0.1.19) for aligning each group of ﬁltered
reads to a corresponding reference sequence. To determine lesion type, frequency,
size, and distribution, all edited reads from each experimental replicate were
combined and aligned, as described above. Alignments were categorized into seven
classes: unedited, SpCas9 indels, Nm/SaCas9 indels, precise deletions, imprecise
deletions, SpCas9+Nm/SaCas9 indels, and inversions. Lesion types and frequencies
were then cataloged in a text output format at each base using bam-readcount. For
each treatment group, the average background lesion frequencies (based on lesion
type, position and frequency) of the triplicate-negative control group were
subtracted to obtain the nuclease-dependent lesion frequencies. Next, using R, a
system for statistical computation and graphics42, we assessed whether the
Cas9–Cas9 fusions resulted in different lesion rates from two independent Cas9s.
Percent of lesion rates were transformed using logit function followed by one-way
analysis of variance (ANOVA) with the Randomized Complete Block Design
(Supplementary Figures 5, 6, 10) or Completely Randomized Design (Fig. 6b). BH-
adjusted p-values were calculated to counteract the problem of multiple
comparisons of the data shown in Fig. 6b (ref. 43). Statistical testing for the AAVS1
extended deletion analysis (Supplementary Figure 7) was performed using a
Student’s t-test for comparison of the fraction of precise deletions for the
independent and fusion nucleases.
For UMI analysis, we ﬁrst used BWA (version 0.7.5) and SAMtools (version
0.1.19) for aligning each group of ﬁltered merged-read pairs to a corresponding
reference sequence ignoring the unique molecular barcodes. Next, we used a
custom Python and PySAM script to process mapped reads into counts of UMI-
labeled reads for each target, the mapped reads are ﬁltered by setting mapping
value larger than 30. Alignments were categorized into seven classes: unedited,
SpCas9 indels, Nm/SaCas9 indels, precise deletions, imprecise deletions, SpCas9
+Nm/SaCas9 indels, and inversions. Next, we identiﬁed UMI duplicates and the
minimal set of amplicons that can account for the full set of reads with unique
UMIs. For each unique UMI, a minimum of four observations of the same
sequence were required to consider the sequence to have a low likelihood of being
an artifact (sequencing error in the UMI element). For those sequences meeting
this threshold, the base sequences for a unique molecular barcode are consolidated
to one read per molecule, and the reads with unique UMI were counted. The same
pipeline was used separately for each sample with deletions spanning less than 50
bp. For the analysis of larger deletions in the AAVS1 locus, we ﬁltered raw reads
according to their quality via FASTQ for a mean PHRED quality score above 30
and a minimum per base score above 24. These sequences were not ﬁltered based
on their mapping value, as the mapping score for large deletions is low. The
resulting UMIs number tables were concatenated and loaded into GraphPad Prism
7 for data visualization.
GUIDE-seq off-target analysis. GUIDE-seq12 was performed with the following
adjustments to the original protocol. HEK293T cells were transfected using Poly-
fect transfection reagent (Qiagen) according to the manufacturer’s suggested
protocol with 50 ng of single nuclease (SpCas9WT, NmCas9WT, SaCas9WT) or 100
ng Cas9–Cas9 fusion expression plasmid, 50 ng of each sgRNA expressing plasmid,
50 ng of a mCherry expression plasmid and 5 pmol of annealed GUIDE-seq oli-
gonucleotide. 72 h after transfection, genomic DNA was extracted with GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma) according to the manufacturer’s
suggested protocol. We prepared the GUIDE-seq library with the original adaptors
according to protocols described by Joung and colleagues12. Each library was
indexed within the P5 and P7 adaptors for multiplex sequencing. The libraries were
deep-sequenced as a pool using two paired-end 150-bp Illumina MiSeq runs.
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Deep sequencing data from the GUIDE-seq experiment was analyzed using the
Bioconductor Package GUIDEseq (v1.4.1)44. The window size for peak aggregation
was set to 50 bp. Off-target site identiﬁcation parameters were set for SpCas9 as
follows: min.reads= 2, min.reads.per.lib= 1, distance.threshold= 70, min.peak.
score.1strandOnly= 2, upstream= 20, downstream= 20, max.mismatch= 6,
PAM.pattern= “NNN$”, allowed.mismatch.PAM= 2. For NmCas9, same
parameters were used except the following: PAM.size= 8, PAM= “NNNNGHTT”,
PAM.pattern= “NNNNGNNN$“, allowed.mismatch.PAM= 3, max.mismatch=
9. For SaCas9, same parameters were used as for SpCas9 except the
following: PAM.size= 6, PAM= “NNGRRT”, PAM.pattern= “NNGNNN$“,
allowed.mismatch.PAM= 3, max.mismatch= 6. The potential off-target
sites identiﬁed for each nuclease are listed in Supplementary Data 2. The speciﬁcity
ratio is calculated as the sum of the unique GUIDE-seq reads at the target site
divided by all of the unique reads at all of the computationally identiﬁed off-target
sites.
Estimation of Cas–Cas9 target sites within human genome. To identify
potential SpCas9–SaCas9 and SpCas9–NmCas9 target sites across the human
genome, we used a Perl regular expression to search for all possible target sites
chromosome by chromosome using two sets of parameters: “canonical targets”
SpCas9 PAM=NGG, SaCas9 PAM=GRRT, NmCas9 PAM=GATT, Site
orientation=D1 or D2, spacing between edges of Cas9 target sites= 10–30 bp, or
“expanded range” SpCas9 PAM=NNG or NGN, SaCas9 PAM=GRRT, NmCas9
PAM=GATT, Site orientation=D1 or D2, spacing between edges of Cas9 target
sites= 10–100 bp. The number of potential target sites for SpCas9–SaCas9 and
SpCas9–NmCas9 were compared to the number of potential sites for SpCas9
within the genome determined by the occurrence of an NGG PAM.
Data availability
Illumina Sequencing data have been submitted to the Sequence Read Archive.
These datasets are available under BioProject Accession number PRJNA496245.
Statistical calculations are found in Supplementary Data 1. The authors declare that
all other data supporting the ﬁndings of this study are available within the paper
and its Supplementary Information ﬁles or upon reasonable request.
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